Abound Bio is focused on developing novel antibody-based biological therapeutics aimed at addressing unmet medical needs, particularly in oncology and infectious diseases. The company employs advanced biotechnological approaches to create innovative therapies that can significantly improve patient outcomes. By leveraging its expertise in antibody engineering, Abound Bio aims to design and produce highly specific and effective treatments that target disease mechanisms, thereby enhancing the quality of life for patients suffering from serious health conditions.

Since its acquisition by Galapagos in 2022, Abound Bio has been integrated into a broader mission to transform patient care through cutting-edge science and innovation. The collaboration emphasizes a commitment to sustainability and transparency, ensuring that the development of new therapies aligns with ethical practices and addresses the needs of patients and the healthcare community. Through ongoing research and clinical trials, Abound Bio is dedicated to pioneering advancements in therapeutic options, particularly in the fields of oncology and immunology.

United States

Abound Bio was acquired by Galapagos. Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Abound Bio

Company Details